Immune Pharmaceuticals Announces Publication of New Data on Eotaxin-1 in IBD; Patient Enrollment in Phase II UC Trial Continues

February 27, 2016

NEW YORK, Feb. 24, 2016 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP), “Immune”, a clinical-stage biopharmaceutical company, announces publication of new data on the role of eotaxin-1 in Ulcerative Colitis (UC) and Crohn’s Disease (CD). The article, published in Digestive Disease Science 1, presents results of an observational clinical study intended to characterize serum and intestinal…

Search

RECENT PRESS RELEASES

Related Post

California considers climate superfund bill to hold fossil fuel firms accountable

California considers climate superfund bill to hold fossil fuel firms accountable

January 15, 2025|0 Comments
How did the Palisades Fire start? Residents point to New Year’s Day blaze in same area
How did the Palisades Fire start? Residents point to New Year’s Day blaze in same area
Gallery

How did the Palisades Fire start? Residents point to New Year’s Day blaze in same area

January 15, 2025|0 Comments
Inside Meta’s race to beat OpenAI: “We need to learn how to build frontier and win this race”
Inside Meta’s race to beat OpenAI: “We need to learn how to build frontier and win this race”
Gallery

Inside Meta’s race to beat OpenAI: “We need to learn how to build frontier and win this race”

January 15, 2025|0 Comments
Meta just flipped the switch that prevents misinformation from spreading in the United States
Meta just flipped the switch that prevents misinformation from spreading in the United States
Gallery

Meta just flipped the switch that prevents misinformation from spreading in the United States

January 15, 2025|0 Comments